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A B S T R A C T
Development of a class of bicyclic inhibitors of the Plasmodium falciparum cyclic GMP-dependent protein kinase
(PfPKG), starting from known compounds with activity against a related parasite PKG orthologue, is reported.
Examination of key sub-structural elements led to new compounds with good levels of inhibitory activity against
the recombinant kinase and in vitro activity against the parasite. Key examples were shown to possess en-
couraging in vitro ADME properties, and computational analysis provided valuable insight into the origins of the
observed activity profiles.
Malaria is one of the most prevalent infectious diseases of the de-
veloping world whose causative agent in humans is the protozoan
parasite Plasmodium, with most deaths caused by the P. falciparum
species. Despite being largely preventable and treatable, it is currently
responsible for almost 0.5 million deaths per year, with young children
and pregnant women in sub-Saharan Africa particularly at risk.1 The
disease also continues to present significant public health policy, social
and economic challenges in developing world countries,2 with
mounting concern about the rapid spread of resistance to current
standard antimalarial drugs. The development of structurally and me-
chanistically novel malaria treatments is urgently required to add to the
control tools and advance eradication of the disease.3
There is a growing body of evidence to suggest that members of the
P. falciparum kinome play important roles in multiple stages of the
parasite lifecycle.4,5 Among these, P. falciparum cGMP-dependent pro-
tein kinase (PfPKG) is attracting considerable interest as a promising
antimalarial drug target. Chemical inhibitors of this enzyme have de-
monstrated prevention of merozoite egress6 and invasion,7 gameto-
genesis,8 ookinete motility,9 liver cell invasion10 and sporozoite moti-
lity.11 These data continue to suggest that PfPKG remains an appealing
drug target for developing new anti-malarial small molecules.
We have recently reported studies on thiazoles12 (derived from
compound 113) and on imidazo[4,5-b]pyridines as potent and selective
inhibitors of PfPKG.14 Using the known compound 215 as a starting
point, we prepared new bicyclic analogues which displayed potent in-
hibitory activity against the enzyme and in vitro blood stage anti-
parasite activity, good selectivity against human kinases and significant
in vivo target-driven efficacy.14 However, important ADME parameters
were thought to remain outside desirable ranges in some cases. Our aim
was to investigate key structural motifs in 2 in ways that would address
these important physicochemical property considerations, whilst
maintaining cell potency and lipophilic ligand efficiency.16
We considered that three important initial areas of focus on the
structure of 2 would aid the achievement of these objectives. The
pyrimidine and its 2-substituent offered opportunities to influence po-
tency and to probe the hinge binding motif against recent crystal-
lographic data14 (Figure 1 – A), drawing on our recent studies of a
closely related sub-series based on a thiazole core.12 A second aspect
involved relocating the tertiary amine substituent from its position on
the bicyclic scaffold to within an extended aminopyrimidine (Figure 1 –
B). Finally, alternative bicyclic cores (Figure 1 – C), some containing
additional nitrogen atoms, could contribute to lowering lipophilicity.
Our previous experiences with one such related scaffold17–20 suggested
that more straightforward synthetic access might also be realised.
Herein we report our initial efforts in these areas of work and show how
each guided the development of new SAR understanding towards im-
proved in vitro profiles as described above.
We first prepared compounds with which to probe the proposed
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bidentate 2-aminopyrimidine hinge binding motif. The 4-aminopyr-
imidine isomer 5 was obtained from 4-thiomethyl-6-methylpyrimidine
321 by means of a three-step conversion to intermediate 4, transfor-
mation of the thiomethyl motif and introduction of the diaminomethyl
side chain (Scheme 1). Regioselective iodination of intermediate 622,
followed by mesylation of the alcohol, displacement with dimethyla-
mine and coupling with the appropriate boronic acid gave target
compounds 7–10 in good yields. A larger aryl piperazine substituent12
could be appended to aminopyridine 10 by means of palladium-cata-
lysed arylation, followed by N-deprotection to give 11.
These structural alterations significantly influenced levels of en-
zyme inhibition (Table 1). The regioisomeric aminopyrimidine 5 was
much less active compared to 2 in both biochemical and in vitro blood
stage anti-parasite activity (data not shown) assays.23 The known un-
substituted pyrimidine 715 showed some recovery against the enzyme.
Pyridine 8 was also nearly 40-fold less biochemically active, and other
heterocycles such as 9 showed no improvement.24 Interestingly, little
change was observed on the re-introduction of an amino group in 10.
Introduction of an aryl piperazine motif in 11 resulted in a further drop
in potency, in stark contrast to our previous observations on similarly
extended aminopyrimidines in the thiazole series.12 These data sug-
gested that the 2-aminopyrimidine motif in 2 was likely to provide an
optimal interaction with the hinge region of the enzyme.
Docking of key examples 2, 8 and 11 into a recently published
PfPKG crystal structure (PDB:5DYK)25 provides a possible rationale for
understanding these SAR variations. As shown in Figure 2, the bicyclic
core of each compound occupies a similar position, directing the 4-
fluorophenyl group into a hydrophobic pocket adjacent to the gate-
keeper residue (T618), and positioning the dimethylaminomethyl
group in 2 and 8 to enable charge interactions with two acidic residues
at the solvent interface (E625 and D682). Classical bidentate hydrogen
bond formation to hinge residue V621 contributes significantly to the
high affinity of 2 and explains the lower affinity of 7 and 8. However,
pyridine 8 requires a larger rotation out of plane from the bicyclic core
(32.4° deviation calculated for 8, 16.5° deviation for 2), in order to
avoid steric clash between hydrogen atoms. Introduction of the larger
phenyl piperazine in 11 appeared to allow an edge-face aromatic in-
teraction with Y822 and a relatively long-range charge interaction with
E625 at the pocket mouth. Formation of these interactions had been
proposed as a route to obtaining a boost in potency in the thiazole
series.12 In the current case, any benefit is more than offset by rea-
lignment to accommodate this bulky group; this results in weakening of
other key interactions, among which are hinge binding to V621 and
charge interaction between the N,N-dimethylamine group and E625. It
also appears that re-introduction of a bidentate hinge-binding motif in
aminopyridine11 is not sufficient to regain affinity. Though this favours
a more coplanar arrangement of the bicyclic core and hinge-binding
heterocycle, steric clash between the two rings and the increase in
strain energy largely negates any affinity gain. This is reflected in an
intermediate calculated dihedral angle (26.2°) for 11. Hence the current
data suggested retaining the amino pyrimidine motif as a more ap-
propriate choice of hinge binding motif, and one which would best
allow for effective substituent growth towards the mouth of the binding
pocket in future analogues.
We turned our attention to the benzylic tertiary amine group at-
tached to the bicyclic core, and hypothesised that re-positioning it to
become part of the aminopyrimidine substituent would be beneficial for
metabolic stability whilst maintaining potency. In doing so, it was
thought that the deletion of both a tertiary amine and a labile benzylic
methylene group would remove two likely sites for primary in vitro
Figure 1. Structures of compounds 1 and 2, with
planned structural changes to imidazopyridines: A –
probe the hinge binding motif; B – re-position the
basic centre; C – vary the bicyclic scaffold. ADME
properties for 2: mLogD=measured logD; MLM =
% remaining after 30min incubation with mouse
liver microsomes; PAMPA=passive permeability.
Scheme 1. Reagents and conditions: (i) LiHMDS, 4-F-C6H4-CO2Me, THF, -10 °C – rt; (ii) Br2, AcOH, 0 °C – rt; (iii) 2-aminopyridine-4-methanol, EtOH, 4 Å sieves, 80 °C;
(iv) mCPBA, CH2Cl2, rt; (v) aq NH3, THF, microwave, 100 °C; (vi) SOCl2, CH2Cl2, 50 °C; (vii) Me2NH, THF, 0 °C – rt; (viii) NIS, CH2Cl2, MeCN, rt; (ix) MsCl, Et3N,
CH2Cl2, 0 °C, then Me2NH, THF, rt; (x) PdCl2(dppf), ArB(OR)2, Cs2CO3, dioxane, 90 °C; for Ar= 2-aminopyridine only – (xi) Pd(OAc)2, Xantphos, 4-bromophenyl-N-
BOC-piperazine, Cs2CO3, dioxane, 100 °C, then 4M HCl in dioxane, rt.
J.M. Large et al. Bioorganic & Medicinal Chemistry Letters xxx (xxxx) xxx–xxx
2
metabolism. In addition, larger aminopyrimidine substituents had
previously been shown to provide significant additional in vitro po-
tency,12 so we wished to explore whether a larger substituent con-
taining a basic centre or other polar group could provide both potency
and microsomal stability. The required intermediates 12 or 13 could be
assembled using similar chemistry to that described above. The sulfide
12 could be oxidised and easily displaced with more reactive amines, as
shown in Scheme 2. For less nucleophilic substrates, alternative acid-
catalysed displacement conditions using the chloropyrimidine 13
proved to be more suitable, allowing rapid and efficient preparation of
the desired analogues.
We were encouraged to find that early examples such as the simple
alkyl amine 14 showed a promising level of in vitro potency (Table 2).
Conformational constraint in non-basic 15 further supported this ap-
proach, improving activity and maintaining a good ADME profile. By
extending further via a phenyl linker to give aryl piperazine 16, further
significant boosts in both biochemical and anti-malarial activity in a
blood stage hypoxanthine incorporation (HXI) cell-based assay were
obtained. While metabolic stability for 16 remained reasonably good,
other aspects of physicochemistry were likely to be driven by poorer
solubility. Adjusting basicity (as in piperidine 17), or combining with a
change in vector (e.g. pyrazole 18) provided only isolated improve-
ments in ADME properties (eg. solubility for 18).26 The trend of mi-
crosomal stability for the aryl aminopyrimidines 16–18 was unexpected
given their measured logD values, for which there was no convincing
explanation. Taken together, these data suggested that this type of aryl
linked analogue was in many cases able to provide very good levels of
potency, but that a well-balanced overall in vitro profile was not easy to
locate in compounds lacking the basic substituent on the bicyclic core.
To assess the impact of altering the bicyclic core, we selected and
prepared several matched-pair analogues in related [6,5-] ring systems.
The imidazopyrimidines 19 and 20 could be synthesised from the re-
gioisomer of 3 and an appropriate aminopyrimidine in the same way as
described for 5, with separation of the regioisomeric bicyclic inter-
mediates. Benzimidazole 23 could be prepared by oxidation and dis-
placement of intermediate 2123, followed by reduction of the Weinreb
Table 1
Examining the hinge binding motif.
Compound Ar PfPKG pIC50 LLEa
2 8.70 6.2
5 7.06 4.7
715 7.92 5.9
8 7.11 4.2
9 6.92 5.1
10 7.28 5.3
11 6.59 nt
a nt=not tested.
Scheme 2. Reagents and conditions: for 12 – (i) a) mCPBA, CH2Cl2, rt; b) RNH2,
dioxane, 80 °C; for 13 - (ii) RNH2, TFA, sBuOH, 110 °C.
Figure 2. Compounds 2 (left), 8 (centre) and 11 (right) docked into PfPKG, with protein surface coloured by electrostatic potential. Charge-based and H-bonding
interactions and distances are shown in purple, the dihedral angles between the bicyclic core and the hinge-binding heterocycle are shown in red, and the edge-face
interaction between Y822 and the phenyl ring in compound 11 is shown in light blue.
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amide in 22 and reductive amination (Scheme 3).
The imidazopyridazine 26 could be accessed by varying a previous
chemical approach.17 Conversion of bromoketone 2415 to intermediate
25was followed by oxidation of the thiomethyl group and reaction with
ammonia (Scheme 4). Then displacement of the 2-chloro group with the
correct amine gave the target 26. Finally, condensation of the alky-
nylpyrimidine 2727 with an N-aminopyridinium salt gave intermediate
28 and its (undesired) regioisomer. Transformation of the desired re-
gioisomeric product using known chemistry provided the pyr-
azolopyridine 29.
These modifications to the bicyclic core once again resulted in
considerable variation in in vitro activity and ADME profile. The imi-
dazopyrimidine examples 19 and 20 could not in either case match the
biochemical activity, anti-parasite activity or lipophilic efficiency of 2,
though both possessed broadly similar ADME profiles (Table 3). Some
potency was regained in benzimidazole 23, as were further improve-
ments in lipophilicity and metabolic stability, though passive perme-
ability was lower. Whilst offering improvements in synthetic tract-
ability and molecular diversity,17 imidazopyridazine 26 was
significantly less potent and passively permeable. Encouragingly, the
pyrazolopyridine 29 regained the best levels of in vitro activity and li-
pophilic efficiency, though further improvements to a promising ADME
profile proved difficult to locate in additional examples, particularly
with respect to metabolic stability.
Computational calculations again suggested a plausible framework
by which to understand these data. Each bicyclic system bears a con-
served nitrogen atom in the 5-membered ring, but this does not appear
to engage the side chain of residue K570 in a bonding interaction in any
case. A similar observation was made for a crystal structure of the P.
vivax PKG enzyme in complex with 2.14 Generation of electronegative
field isosurfaces28 revealed subtle influences on the hinge binding in-
teraction between the pyrimidine nitrogen atom and the backbone of
residue V621. This important interaction was relatively unperturbed for
2 (and also for 29 – data not shown), but appeared to be significantly
weakened in the case of benzimidazole 23 (Figure 3). Although a
smaller effect seemed to affect the imidazopyrimidines 19 and 20,
higher desolvation penalties due to increased polarity could explain the
lowering of affinity for those molecules. The imidazopyridazine 26
showed an electronegative field isosurface very similar to 2 and 29, but
two additional factors may contribute more significantly to its lower
Table 2
Relocating the polar bicyclic group.
Compound R PfPKG pIC50 Pf HXI pEC50a LLE mLogD MLM % remb PAMPA (nm s−1) Kinetic solubility (µM)a
14 6.07 nt 4.3 1.8 62 82 nt
15 6.88 nt 5.1 1.8 84 145 nt
16 8.60 6.94 4.6 4.0 65 0 9
17 8.30 6.80 5.0 3.3 55 0 0
18 7.00 6.24 4.3 2.7 37 124 237
a nt=not tested.
b % remaining after 30 mins.
Scheme 3. Reagents and conditions: (i) H2O2, Na2WO4·2H2O, AcOH, MeOH, 0 °C – rt; (ii) NH3, THF, dioxane, 60 °C; (iii) DIBAL-H, toluene, -78 °C; (iv) Me2NH, NaBH
(OAc)3, CH2Cl2, THF, rt.
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Scheme 4. Reagents and conditions: (i) 2-amino-6-chloropyridazine, EtOH, 4 Å sieves, 80 °C; (ii) mCPBA, CH2Cl2, rt; (iii) NH3, dioxane, 115 °C; (iv) Me2NCH2CH2NH2,
DIPEA, NMP, 180 °C; (v) 1-amino-3-(hydroxymethyl)pyridinium iodide, DBU, CH3CN, rt; (vi) MsCl, Et3N, CH2Cl2, 0 °C; (vii) Me2NH, THF, rt; (viii) H2O2,
Na2WO4·2H2O, AcOH, MeOH, rt; (ix) NH4OAc, sealed tube, 120 °C.
Table 3
Alternative bicyclic cores.
Compound Core R PfPKG pIC50 Pf HXI pEC50a LLE mLogD MLM % remb PAMPA (nm s−1)
2 7-CH2NMe2 8.70 6.44 6.3 2.4 52 110
19 7-CH2NMe2 7.26 5.43 5.2 2.1 59 58
20 7-CH2NMe2 7.09 5.39 5.0 2.1 67 118
23 7-CH2NMe2 7.51 nt 6.3 1.2 78 32
26 6-NH(CH2)2NMe2 6.39 nt 4.8 1.6 68 10
29 7-CH2NMe2 8.39 6.29 5.9 2.5 22 185
a nt=not tested.
b % remaining after 30 mins.
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affinity. Firstly, the electrostatic repulsion between the nitrogen atoms
on the core and pyrimidine ring appears likely to deplanarise that part
of the molecule, weakening key interactions in doing so. Secondly, the
pendent amine employed may result in less optimal positioning of the
charged group, despite increased polarity and flexibility.
This report has described our initial efforts to develop a series of
bicyclic PfPKG inhibitors, based upon a previously described chemical
starting point. By focusing on key sub-structural motifs, we have both
confirmed and enhanced important SAR and physicochemical trends,
resulting in key examples such as 16 and 29. These two compounds
showed good levels of biochemical and in vitro anti-malarial activity; 29
in particular possessed equivalent mLogD, improved passive perme-
ability and retained a good level of lipophilic ligand efficiency. Docking
and computational analyses provided additional insight into the origins
of the observed structure activity relationships. Studies to refine, ex-
pand and apply this new knowledge to the preparation of further im-
proved compounds will be reported in due course.
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